A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00000675
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Genentech, Inc.
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Study Completion Date : No date given
Collier A, Katzenstein D, Coombs R, Holodniy M, Mordenti J, Arditti D, Ammann A, Merigan T, Corey L. Safety and pharmacokinetics of intravenous recombinant CD4 immunoadhesin (RCD4-IGG) (AIDS Clinical Trials Group Protocol 121). Int Conf AIDS. 1990 Jun 20-23;6(3):206 (abstract no SB480)